Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.
Alice BesseyJames B ChilcottJoanna LeavissAnthea SuttonPublished in: Orphanet journal of rare diseases (2018)
Including screening of boys for X-ALD into an existing tandem mass spectrometry based newborn screening programme is projected to reduce lifetime costs and improve outcomes for those with CCALD. The potential disbenefit to those identified with non-CCALD conditions would need to be substantial in order to outweigh the benefit to those with CCALD. Further evidence is required on the potential QALY impact of early diagnosis both for non-CCALD X-ALD and other peroxisomal disorders. The favourable economic results are driven by estimated reductions in the social care and education costs.
Keyphrases
- tandem mass spectrometry
- healthcare
- high performance liquid chromatography
- liquid chromatography
- quality improvement
- simultaneous determination
- palliative care
- clinical trial
- mental health
- mass spectrometry
- risk assessment
- metabolic syndrome
- randomized controlled trial
- type diabetes
- adipose tissue
- human health
- pain management
- skeletal muscle
- solid phase extraction